HAMPTON, N.J. , April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the presentation of promising data from the Company’s growing bispecific platform at the American Association of Cancer Research (AACR) Annual Meeting 2021 being held April 10 th – 15 th .

HAMPTON, N.J. , March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020 . “Celldex made significant progress across our pipeline in 2020 and today continued this momentum

--CDX-0159 generally well tolerated to date-- --Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J. , March 29, 2021 (GLOBE NEWSWIRE) --   Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported interim data from the Company’s ongoing, open label clinical trial of CDX-0159 in patients

HAMPTON, N.J. , March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company’s participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference . The presentation for the virtual conference was prerecorded and will be accessible to

--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Potential to expand future CDX-0159 development beyond chronic urticarias to chronic pruritic diseases and

HAMPTON, N.J. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. ET .

HAMPTON, N.J. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez , Esq. to Senior Vice President and General Counsel, effective January 1, 2021 . Over the span of a 30 year career in the biopharmaceutical industry, Mr.

HAMPTON, N.J. , Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria

HAMPTON, N.J. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 pm ET .

--   A gonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from multiple presentations at